Table 3.

Cox regression multivariate analysis for DFS in the training and validation cohorts

Training cohortValidation cohort
nHR (95% CI)PnHR (95% CI)P
Stage0.0010.343
 Stage II60 (29.7%)1 (reference)45 (25.42%)1 (reference)
 Stage III142 (70.3%)3.03 (1.43–6.43)132 (74.57%)1.53 (0.63–3.67)
Lymphovascular invasion0.003<0.001
 No114 (56.43%)1 (reference)101 (57.06%)1 (reference)
 Yes88 (43.56%)2.26 (1.31–3.87)76 (43.94%)4.67 (2.28–9.55)
Bowel perforation0.349<0.001
 No161 (79.7%)1 (reference)157 (88.71%)1 (reference)
 Yes41 (20.3%)1.32 (0.74–2.35)20 (11.29%)3.56 (1.88–6.77)
SELE rs3917412 + MTHFR rs18011330.0030.035
 2 favorable (SELE G/A-A/A and MTHFR C/T-C/C)71 (38.17%)1 (reference)63 (38.41%)1 (reference)
 1 favorable (SELE G/A-A/A or MTHFR C/T-C/C)100 (53.76%)1.68 (0.93–3.03)0.08792 (56.09%)1.99 (1.013–3.909)0.046
 2 unfavorable (SELE G/G and MTHFR T/T)15 (8.06%)4.103 (1.803–9.33)0.0019 (5.48%)3.56 (1.25–10.15)0.017